Adult Dosing

Bacterial Conjunctivitis

• Instill 1 drop in the affected eye(s) bid x 7 days

Pediatric Dosing

• Safety and effectiveness in pediatric patients <4 months of age have not been established

Bacterial Conjunctivitis

• 4 months: Instill 1 drop in the affected eye(s) bid x 7 days

[Outline]

• Adult Dosing
• Pediatric Dosing

• Treatment of bacterial conjunctivitis

• Hypersensitivity to any of the ingredients of the product

• N/A

Renal Dose Adjustment

• Renal impairment: No dose adjustments

Hepatic Dose Adjustment

• Hepatic impairment: No dose adjustments

• Ophthalmic solution should not be injected subconjunctivally or introduced directly into the anterior chamber of the eye
• Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have occurred with systemic quinolone therapy, even following a single dose
• Discontinue immediately at the first sign of a rash or allergic reaction
• Prolonged administration may result in overgrowth of non-susceptible organisms causing superinfection, including fungi. Discontinue use and institute alternate therapy in such cases
• Avoid contaminating the contents by not touching the applicator tip with material from the eye, fingers, or other source
• Advise patients to avoid using contact lenses during treatment if they have signs and symptoms of bacterial conjunctivitis

Moxeza, Vigamox interacts with :

	Antacids
	Calcium Polycarbophil
	Carafate
	Didanosine
	FiberCon
	Iron Products
	Sucralfate
	Videx
	Videx EC
	Zinc

Pregnancy Category:C

Breastfeeding: Safety unknown; maternal use of the ophthalmic solution presents negligible risk to the nursing infant. This information is based upon LactMed database (available at http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT last accessed 24 March 2011. Manufacturer advises caution.

• EENT: Superinfection, ocular irritation, conjunctivitis, subconjunctival hemorrhage
• MISC: Hypersensitivity reactions, fever

• Fluoroquinolone; inhibits bacterial DNA synthesis by inhibiting DNA gyrase and topoisomerase IV enzymes
• Minimal systemic absorption following ophthalmic administration
• Metabolism: Unknown
• Excretion: Unknown
• Half-life: Unknown

US Trade Name(s)

• Moxeza
• Vigamox

US Availability

Moxeza, Vigamox

• OPTH SOLN: 0.5%

Canadian Trade Name(s)

• Vigamox

Canadian Availability

Vigamox

• OPTH SOLN: 0.5%

UK Trade Name(s)

• Moxivig

UK Availability

Moxivig

• OPTH SOLN: 0.5%

Australian Trade Name(s)

• N/A

Australian Availability

• N/A

[Outline]

Antimicrobials

Antibiotics

Quinolones

Infectious Disease

Antibiotics

Quinolones

Antimicrobials

Ophthalmic Anti-infectives

Infectious Disease

Ophthalmic Anti-infectives

Ophthalmic

Ophthalmic Anti-infectives

Pricing data from www.DrugStore.com in U.S.A.

• Vigamox 0.5 % SOLN [Bottle] (ALCON VISION)
  3 % = $96.46
  9 % = $271.38

Warning: This pricing information is subject to change at the sole discretion of DS Pharmacy. For the most current and up-to-date pricing information, please visit drugstore.com.